Long title
A randomized, double-blind, placebo-controlled Phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26COVS1 in adults aged 18 to 65 years, inclusive and adults aged 65 years and older.
Date receipt dossier
EU record number
J&JBE-018_004
EudraCT number
2020-001483-28
Company / Sponsor
Janssen Vaccines & Prevention B.V.
Phase
I/II a
Treated organism
Humans
Indication category
Infectious disease
Disease
COVID-19
Therapeutic approach
Prevention
Genetic modification
Recombinant Adenoviral vector serotype 26 expressing the spike glycoprotein 1 from SARS-CoV2
Method of transfer of nucleic acid of interest
Not applicable
Administered biological material
Recombinant Adenoviral vector serotype 26 expressing the spike glycoprotein 1 from SARS-CoV2
Route of administration
Intramuscular
Locations in Belgium
Janssen Pharmaceutica N.V., Clinical Pharmacology Unit (Jan Palfijn ziekenhuis)
Type of procedure
Contained use only
Current status
Under evaluation
Pharmaceutical study code
Ad26-COVID19